Category: MS Research Study and Reports

Apr 16, 2024 – Press Release: Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Media / Press Releases Tuesday, Apr 16, 2024 Results from the Phase III study showed that subcutaneous (SC) injection was consistent with…

Stuart Schlossman

Redefining Relapse in Efficacy Measures for Multiple Sclerosis Treatments

By: Stephen Krieger, MD; Enrique Alvarez, MD, PhD In this poster, Enrique Alvarez, MD, PhD., (from university of Colorado at…

Stuart Schlossman

Featured image for “Will Frexalimab replace the anti-CD20s?”

Will Frexalimab replace the anti-CD20s?

It is clear to me, and it should be clear to my colleagues, that anti-CD20 therapies have a limited shelf-life…

Stuart Schlossman

Dark rim on MS lesions seen with standard MRI may mark activity

Possible way of spotting in clinic rim lesions known to drive progression By Marisa Wexler, MS on 02/26/2024 An imaging…

Stuart Schlossman

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (sanofi.com)

 Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS Paris, February 15, 2024. The…

Stuart Schlossman

Nitric oxide metabolites in blood could aid diagnosis of MS: Study

Molecules were elevated in study of RRMS, PPMS patients by Lindsey Shapiro, PhD | February 13, 2024 Measuring levels of nitric oxide metabolites…

Stuart Schlossman

Ancient DNA From Eurasian Herders Sheds Light on the Origins of Multiple Sclerosis

 January 14, 2014 Genetic variants linked to the risk of MS were brought to Europe during a migration around 5,000…

Stuart Schlossman

Blood levels of GFAP protein may predict disease progression in PPMS

 Risk of disability worsening nearly 3 times greater with high GFAP: Study The ongoing worsening of disability among people with primary…

Stuart Schlossman

EU agency OKs study of therapy to improve mitochondrial function

 Trial of MP101 to enroll patients with MS, other neurodegenerative diseases by Andrea Lobo, PhD | January 16, 2024 Mitochon Pharmaceuticals is launching a…

Stuart Schlossman

Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy

  Abstract Background: After natalizumab discontinuation severe relapses can occur despite pregnancy, but third trimester exposure is associated with neonatal haematological…

Stuart Schlossman

Categories

Latest Blog Posts